173 related articles for article (PubMed ID: 18751432)
1. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma.
Klepzig M; Sauer-Eppel H; Jonas D; Oremek GM
Anticancer Res; 2008; 28(4C):2443-6. PubMed ID: 18751432
[TBL] [Abstract][Full Text] [Related]
2. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
4. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
5. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
6. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
Moseshvili E; Joseph DJ; Spry NA; Cohen RJ; Abreu A; Kautto A; Denham JW
J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases.
Chrapko BE; Nocuń A; Gołebiewska R; Jankowska H; Zaorska-Rajca J
Nucl Med Rev Cent East Eur; 2005; 8(2):100-4. PubMed ID: 16437394
[TBL] [Abstract][Full Text] [Related]
8. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
[TBL] [Abstract][Full Text] [Related]
9. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Saito S; Tachibana M; Murai M
J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
11. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
Igawa T; Sakai H; Kanetake H; Saito Y
Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
[TBL] [Abstract][Full Text] [Related]
12. Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases.
Marin L; Koivula MK; Jukkola-Vuorinen A; Leino A; Risteli J
Ann Clin Biochem; 2011 Sep; 48(Pt 5):447-51. PubMed ID: 21733929
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma.
Gao Y; Lu H; Luo Q; Wu X; Sheng S
Clin Biochem; 2010 Feb; 43(3):291-5. PubMed ID: 19732762
[TBL] [Abstract][Full Text] [Related]
14. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Koopmans N; de Jong IJ; Breeuwsma AJ; van der Veer E
J Urol; 2007 Sep; 178(3 Pt 1):849-53; discussion 853; quiz 1129. PubMed ID: 17631330
[TBL] [Abstract][Full Text] [Related]
15. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
Gascoin-Lachambre G; Trivin C; Brauner R; Souberbielle JC
Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
17. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival.
Thurairaja R; Iles RK; Jefferson K; McFarlane JP; Persad RA
Urol Int; 2006; 76(1):67-71. PubMed ID: 16401924
[TBL] [Abstract][Full Text] [Related]
18. PINP as serum marker of metastatic spread to the bone in breast cancer patients.
Lüftner D; Jozereau D; Schildhauer S; Geppert R; Müller C; Fiolka G; Wernecke KD; Possinger K
Anticancer Res; 2005; 25(3A):1491-9. PubMed ID: 16033050
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Stenzl A; Beger G; Rinnab L; Kuczyk MA; Kuefer R
Urol Int; 2007; 79(1):41-3. PubMed ID: 17627167
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
